Literature DB >> 33450869

Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.

Michela Codini1, Mercedes Garcia-Gil2,3, Elisabetta Albi1.   

Abstract

Lipid rafts are critical cell membrane lipid platforms enriched in sphingolipid and cholesterol content involved in diverse cellular processes. They have been proposed to influence membrane properties and to accommodate receptors within themselves by facilitating their interaction with ligands. Over the past decade, technical advances have improved our understanding of lipid rafts as bioactive structures. In this review, we will cover the more recent findings about cholesterol, sphingolipids and lipid rafts located in cellular and nuclear membranes in cancer. Collectively, the data provide insights on the role of lipid rafts as biomolecular targets in cancer with good perspectives for the development of innovative therapeutic strategies.

Entities:  

Keywords:  cancer; cholesterol; lipid raft; sphingolipid; therapeutic target

Mesh:

Substances:

Year:  2021        PMID: 33450869      PMCID: PMC7828315          DOI: 10.3390/ijms22020726

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  148 in total

Review 1.  Clinical application of ceramide in cancer treatment.

Authors:  Kazuki Moro; Masayuki Nagahashi; Emmanuel Gabriel; Kazuaki Takabe; Toshifumi Wakai
Journal:  Breast Cancer       Date:  2019-04-08       Impact factor: 4.239

2.  β-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.

Authors:  Ling Xu; Tianshu Guo; Xiujuan Qu; Xuejun Hu; Ye Zhang; Xiaofang Che; Huicong Song; Jing Gong; Rui Ma; Ce Li; Yibo Fan; Yanju Ma; Kezuo Hou; Peihong Wu; Hang Dong; Yunpeng Liu
Journal:  Cell Biol Int       Date:  2018-07-23       Impact factor: 3.612

3.  Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.

Authors:  Sitapriya Moorthi; Tara Ann Burns; Gui-Qin Yu; Chiara Luberto
Journal:  FASEB J       Date:  2018-03-13       Impact factor: 5.191

4.  Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.

Authors:  Mary E Irwin; Natacha Bohin; Julie L Boerner
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

5.  Sphingomyelin Metabolism Is a Regulator of K-Ras Function.

Authors:  Dharini van der Hoeven; Kwang-Jin Cho; Yong Zhou; Xiaoping Ma; Wei Chen; Ali Naji; Dina Montufar-Solis; Yan Zuo; Sarah E Kovar; Kandice R Levental; Jeffrey A Frost; Ransome van der Hoeven; John F Hancock
Journal:  Mol Cell Biol       Date:  2018-01-16       Impact factor: 4.272

6.  Motility and stem cell properties induced by the epithelial-mesenchymal transition require destabilization of lipid rafts.

Authors:  Michael J Tisza; Weina Zhao; Jessie S R Fuentes; Sara Prijic; Xiaoling Chen; Ilya Levental; Jeffrey T Chang
Journal:  Oncotarget       Date:  2016-08-09

7.  Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics.

Authors:  Zhao Li; Ming Guan; Yu Lin; Xiao Cui; Yangyang Zhang; Zhenwen Zhao; Jiye Zhu
Journal:  Int J Mol Sci       Date:  2017-11-28       Impact factor: 5.923

8.  Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.

Authors:  Juan Zeng; Heying Zhang; Yonggang Tan; Cheng Sun; Yusi Liang; Jinyang Yu; Huawei Zou
Journal:  BMC Cancer       Date:  2018-05-30       Impact factor: 4.430

Review 9.  Host Lipid Rafts as the Gates for Listeria monocytogenes Infection: A Mini-Review.

Authors:  Yu-Huan Tsai; Wei-Lin Chen
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

10.  Hydroxypropyl‑β‑cyclodextrin attenuates the epithelial‑to‑mesenchymal transition via endoplasmic reticulum stress in MDA‑MB‑231 breast cancer cells.

Authors:  Yifan Wu; Yiyang Zhao; Xuanhong He; Zhiqiang He; Tian Wang; Linxi Wan; Lai Chen; Nianlong Yan
Journal:  Mol Med Rep       Date:  2019-11-06       Impact factor: 2.952

View more
  7 in total

Review 1.  Lipidomic and Membrane Mechanical Signatures in Triple-Negative Breast Cancer: Scope for Membrane-Based Theranostics.

Authors:  Ruchika Dadhich; Shobhna Kapoor
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

Review 2.  Hypercholesterolemia in Cancer and in Anorexia Nervosa: A Hypothesis for a Crosstalk.

Authors:  Giulia Gizzi; Samuela Cataldi; Claudia Mazzeschi; Elisa Delvecchio; Maria Rachele Ceccarini; Michela Codini; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 3.  Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.

Authors:  Johnson Ung; Su-Fern Tan; Todd E Fox; Jeremy J P Shaw; Luke R Vass; Pedro Costa-Pinheiro; Francine E Garrett-Bakelman; Michael K Keng; Arati Sharma; David F Claxton; Ross L Levine; Martin S Tallman; Myles C Cabot; Mark Kester; David J Feith; Thomas P Loughran
Journal:  Blood Rev       Date:  2022-04-09       Impact factor: 10.626

4.  A UHPLC-Mass Spectrometry View of Human Melanocytic Cells Uncovers Potential Lipid Biomarkers of Melanoma.

Authors:  Arantza Perez-Valle; Beatriz Abad-García; Olatz Fresnedo; Gabriel Barreda-Gómez; Patricia Aspichueta; Aintzane Asumendi; Egoitz Astigarraga; José A Fernández; María Dolores Boyano; Begoña Ochoa
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

Review 5.  Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.

Authors:  Doris Loh; Russel J Reiter
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

Review 6.  Inimitable Impacts of Ceramides on Lipid Rafts Formed in Artificial and Natural Cell Membranes.

Authors:  Masanao Kinoshita; Nobuaki Matsumori
Journal:  Membranes (Basel)       Date:  2022-07-23

Review 7.  Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Authors:  Meng-Ying Cui; Xing Yi; Zhen-Zhen Cao; Dan-Xia Zhu; Jun Wu
Journal:  J Oncol       Date:  2022-09-05       Impact factor: 4.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.